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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder resulting in
dementia and eventual death. It is the leading cause of dementia and the number of
cases are projected to rise in the next few decades. Pathological hallmarks of AD include
the presence of hyperphosphorylated tau and amyloid protein deposition. Currently,
these pathological biomarkers are detected either through cerebrospinal fluid analysis,
brain imaging or post-mortem. Though effective, these methods are not widely available
due to issues such as the difficulty in acquiring samples, lack of infrastructure or high
cost. Given that the eye possesses clear optics and shares many neural and vascular
similarities to the brain, it offers a direct window to cerebral pathology. These unique
characteristics lend itself to being a relatively inexpensive biomarker for AD which carries
the potential for wide implementation. The development of ocular biomarkers can have
far implications in the discovery of treatments which can improve the quality of lives of
patients. In this review, we consider the current evidence for ocular biomarkers in AD and
explore potential future avenues of research in this area.
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INTRODUCTION
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disease leading to severe
cognitive loss and eventual death. Of the dementias, AD is the most common, accounting for
between 60 and 70% of all dementias, depending on geography (WHO, 2012). Cohort studies
around the world show that the number of people with AD increases with age, with roughly 1
in 5 people suffering from AD by the age of 85 (Figure 1).
The risk of developing the disease with age doubles every 5.9 years from 3.1 per 1000 persons
aged 60–64 to 175 persons per 1000 at age 95+ (WHO, 2012), making age the strongest risk factor
for AD. Characteristic to the disease is the profound atrophy of the brain accompanied by amyloid-
beta (Aβ) plaques and the presence of tau neurofibrillary tangles (NFTs). Besides aging, genetics
play a major role in the development of sporadic AD. Carriers of the apolipoprotein E (APOE) ǫ4
allele (13.7% of the world’s population) face an increased risk of developing the disease (Farrer et al.,
1997), depending on whether they have one or two copies of the ǫ4 allele. The estimated lifetime
risk of developing the disease is higher in women with one (30%) or two (60%) copies of the ǫ4
allele, compared with men (23 and 51% respectively, Genin et al., 2011). Environmental factors for
the disease (Figure 2) include diabetes mellitus, midlife hypertension, present smoking, depression,
cognitive inactivity, physical inactivity, obesity, level of education, lack of social engagement
(Flicker, 2010; Barnes and Yaffe, 2011). These modifiable factors (Table 1) carry varying degrees
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FIGURE 1 | Dementia world prevalence by age. Data based on
meta-analyzed estimates of dementia prevalence (%) generated from Poisson
random effects models from WHO (2012).
of risk and in combination may account for up to half of the AD
cases worldwide (Barnes and Yaffe, 2011).
At present, physicians make the diagnosis of AD when
patients already exhibit early cognitive losses. The diagnosis
is formalized through mental state or cognitive examinations,
alongside vascular and neurological assessments to rule out other
causes (Burns and Iliffe, 2009). These tests signify the beginning
of the irreversible process leading to dementia. The diagnosis
is only confirmed post mortem though an examination of the
brain. At present, the average survival from diagnosis to death
is 4.6 years, affording little opportunity for treatment outside of
palliative care. Figure 3 summarizes the mechanisms leading to
the formation of Aβ plaques and tau tangles, both of which are
hallmarks of the condition.
Significant advances have been made in the development of
ante mortem diagnostic tools or biomarkers for the disease.
Biomarkers or “surrogate measures” of a disease are useful
because they enable early diagnosis. Moreover, a good biomarker
also enables assessment of drug efficacy both in the laboratory
and in the clinic. Tools that can reliably triage drugs that are
worth taking forward into progressively more expensive Phase
I, II, and III clinical trial phases would considerably reduce the
cost of drug development. Techniques that are simple, non-
invasive, quantitative and objective lend themselves well to being
biomarkers for preclinical and clinical trials. There is a growing
need for a biomarker in Alzheimer’s disease as recent clinical
findings suggest that successful treatment needs to start in the
prodromal stages of the disease (Ising et al., 2015). How such
prodromal stages can be identified is thus of critical importance.
At present, the most well established biomarkers include those
found in cerebrospinal fluid (CSF) (Aβ-42, T-tau, p-tau) and in
the brain (fluorodeoxyglucose [FDG]- and Pittsburg Compound
B [PiB]- Positron Emission Tomography (PET) with reported
sensitivities and specificities of about 0.8 (Rabinovici et al., 2011;
Ferreira et al., 2014). Whilst these methods have considerably
advanced our understanding of the disease, clinically they
fall short of the criteria necessary for large-scale population
screening. Such methods can also be expensive, require repeat
exposure to radiation (PET imaging) or are invasive (lumbar
puncture to obtain CSF sample). The search for AD biomarkers
has expanded to include other forms of brain imaging such as
near infrared and brain volume scans (Hoffman et al., 2000;
Csernansky et al., 2004; Klunk et al., 2004; Hintersteiner et al.,
2005), as well as assays of, blood (Koyama et al., 2012), skin (Khan
and Alkon, 2010; Khan et al., 2015), urine (Ghanbari et al., 1998),
odor (Kimball et al., 2016), and olfactory deficits (Devanand et al.,
2000; Tabert et al., 2005).
Given that many Alzheimer’s sufferers report visual symptoms
(Schlotterer et al., 1984; Sadun et al., 1987; Cronin-Golomb et al.,
1993), there has been an increased interest in potential ocular
biomarkers. Indeed, there have been reports that some visual
symptoms can precede the onset of dementia, and have been
attributed to the development of senile plaques and tangles in
the visual regions of the brain (Mentis et al., 1996; McKee et al.,
2006; Brewer and Barton, 2014). In addition, a visual variant
of AD (VVAD) affecting relatively younger persons has been
identified, though it is important to distinguish this as a separate
pathophysiological entity known as posterior cortical atrophy.
Patients suffering from VVAD typically first present with visual
symptoms in the fifth or sixth decade of life and eventually the
cognitive decline follows the course more typically seen in AD
(Levine et al., 1993; Lee and Martin, 2004; Kaeser et al., 2015).
In addition to potentially important early visual changes, the
eye is very accessible and the retina can be easily imaged, thus
making ocular biomarkers attractive. Figure 4 summarizes the
mechanisms thought to be involved in AD. Along this sequence
of pathological changes are opportunities for various biomarkers
including those involving the eye. These will be discussed in
greater detail below.
RETINAL BIOMARKERS
Retinal Nerve Fiber Layer and Optic Nerve
The first histological evidence for retinal abnormalities in AD
was presented by Hinton et al. (1986) who found widespread
ganglion cell losses (the output neurons of the eye), retinal nerve
fiber layer thinning (RNFL, ganglion cell axons) and optic nerve
degeneration in AD versus healthy controls. This finding was
supported by further studies (Blanks et al., 1996) and provides
an anatomical basis for the use of retinal imaging as a potential
marker of AD. Conventional fundus photography was met with
limited success due to poor nerve fiber resolution (Tsai et al.,
1991; Hedges et al., 1996).
The advent of commercially available, high resolution imaging
modalities such as confocal scanning laser ophthalmoscopy
(SLO) and optical coherence tomography (OCT) allow for
repeatable in vivo quantification of optic nerve topography
and nerve fiber layer. Scanning laser ophthalmoscopy, has the
advantage over conventional photographs of the back of the eye
in that it employs a confocal scanning laser system, thus allowing
for fine depth resolution. Using SLO, Kergoat et al. (2001) and
Danesh-Meyer et al. (2006) demonstrated RNFL thinning in the
macula and peripapillary regions of the retina. Optical coherence
tomography uses low coherence interferometry to detect small
differences in in vivo refractive indices, thus returning high
resolution cross sections of the retina. Using OCT, Berisha et al.
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FIGURE 2 | Risk factors associated with Alzheimer’s disease. This figure shows known associations with Alzheimer’s disease.
TABLE 1 | Risk factors for sporadic Alzheimer’s disease.
Risk factor Relative risk
Lack of social engagement 2.34 (1.18–4.65)
Depression 1.90 (1.55–2.33)
Physical inactivity 1.82 (1.19–2.45)
Hypertension (midlife) 1.61 (1.16–2.24)
Obesity (midlife) 1.60 (1.34–1.92)
Smoking 1.59 (1.15–2.20)
Low education 1.59 (1.35–1.86)
Diabetes 1.39 (1.17–1.66)
This table shows the most commonly identified modifiable risk factors in non-familial AD
and associated relative risk.
(2007) showed overall RNFL thinning in AD, with preference for
superior RNFL loss. This finding is corroborated by a number
of other studies (Lu et al., 2010; Kesler et al., 2011; Kirbas
et al., 2013; Cheung et al., 2015). Cheung et al. (2015) in a large
cohort of AD and patients withmild cognitive impairment (MCI)
showed that the ganglion cell complex (which includes the RNFL,
ganglion cell bodies and their dendrites) at themacula (where this
anatomical feature has the best signal to noise characteristics) is
a more sensitive indicator of the disease than RNFL thickness.
Using this method, they were able to distinguish AD and MCI
from healthy controls after adjusting for age, gender, ethnicity
and OCT signal strength.
A challenge in using the macular ganglion cell complex or
RNFL as biomarkers is its specificity, which is prone to confounds
introduced by aging and other co-existing pathologies such as
glaucoma. Perhaps one way to disambiguate age-related changes
is to assess much wider areas of retina. Age-related changes are
thought to be much more generalized, whereas there is some
evidence for more sectoral losses in diseases such as AD (Parisi
et al., 2001; Berisha et al., 2007; Kesler et al., 2011) and glaucoma.
Whether AD and glaucoma exhibit mutually exclusive patterns of
loss remains to be seen but the recent advent of wide field spectral
domain OCT (Heidelberg Engineering, 2016) will increase our
capacity to topographically map ganglion cell complex and RNFL
changes.
As we learn more about the sequence of events and
the neurodegenerative changes in AD there may be further
opportunities for structural retinal biomarkers. For example,
there is evidence that synapse loss predates neuronal loss and
that the remaining neurons become less well connected to their
synaptic partners. This may account for why synaptic density is
the best correlate of cognitive decline in AD (DeKosky and Scheff,
1990; Scheff et al., 1990, 1993, 2007; Terry et al., 1991; Masliah
et al., 1994; Ingelsson et al., 2004), which may also explain why
the macular ganglion cell complex is more sensitive to MCI than
RNFL thickness as it is inclusive of the inner plexiform layer
containing dendrites of and synaptic connections between retinal
ganglion cells and bipolar cells. In addition to synaptic loss,
early change to neurons includes the disruption of microtubules
(Matsuyama and Jarvik, 1989; Mandelkow et al., 2004; Gasparini
et al., 2011). Ganglion cell axons in the RNFL contain
microtubules, which give rise to the property of birefringence,
whereby their refractive index depends on the polarization of the
incident light. Thus, retinal imaging based on the projection of
polarized light is extremely sensitive to the loss of microtubules in
ganglion cells. Reductions in the birefringence signal as measured
using scanning laser polarimetry (GDx) has been shown to
precede RNFL thinning as measured by OCT (Huang et al., 2006;
Fortune et al., 2008). Polarization sensitive OCT (PS-OCT) is a
rapidly developing imaging modality that may have substantial
implications for retinal imaging in AD (Pircher et al., 2011). By
combining multiple techniques including wider topographical
mapping, comparing inner plexiform and RNFL thickness and
Frontiers in Neuroscience | www.frontiersin.org 3 November 2016 | Volume 10 | Article 536
Lim et al. Ocular Biomarker for Alzheimer’s Disease
FIGURE 3 | Intra- and extra-cellular Alzheimer’s disease hallmark formation. Amyloid precursor protein (APP) transmembrane protein contains between 365
and 770 amino acids beginning with the N- and ending with the C-terminus. β-secretase cleavage leads to the formation of a 99-chain amino acid at the C terminus
(C99). It undergoes further cleavage via γ-secretase to form either Aβ-40 or Aβ-42 monomers. These monomers clump together, taking on complex formations
eventually leading to Aβ plaque formation. Similarly, tau monomers clump to form complex oligomers and eventual neurofibrillary tangles, though this process is less
well understood. Non-pathological APP processing via α-secretase is not shown in the diagram.
birefringence it may be possible to return certain signatures of
loss for aging, glaucoma and AD thus improving specificity for
retinal imaging biomarkers of AD.
Retinal Blood Flow and Vasculature
The most commonly reported vascular problems in AD include
impaired Aβ clearance, blood-brain-barrier compromise,
reduced blood vessel density, smaller vessel diameter
(vasoconstriction) and reduced blood flow (Zlokovic, 2011).
Given similarities between blood vessels in the brain and eye (for
review, see Patton et al., 2005), investigators have considered
the potential usefulness of quantifying the blood vessels in the
eye as a biomarker for AD. Berisha et al. (2007) in a small
cohort showed a significant narrowing of retinal veins and
reduced venous blood flow in AD compared with healthy
controls using a laser Doppler imaging device. Using similar
methodology, Feke et al. (2015) showed that differences in venous
blood flow helped to distinguish MCI from AD and healthy
control.
Larger population studies suggest that retinal vascular
abnormalities are prevalent in AD patients. Using fundus
photography and automated vessel segmentation software,
Cheung et al. (2014) showed (1) a reduction in retinal vessel
caliber; (2) a reduction in fractal dimension—a measure of
the global branching pattern of the retinal vascular tree; (3)
an increase in vessel tortuosity—a measure of the average
degree of curliness/“non-straightness” of retinal vessels; and
(4) no change to vessel branching angles–the angle subtended
between two daughter vessels at each bifurcation. In addition to
these parameters, Frost et al. (2013b) also reported that retinal
vascular abnormalities, namely venular branching asymmetry
and arteriolar length-to-diameter ratios were higher in healthy
individuals with high plaque burden, as measured by PET
imaging using PiB. Williams et al. (2015) (Williams et al.,
2015) reported similar outcome, with the exception of changes
in vascular caliber. The authors suggest that static retinal
photographs may be more variable due to changes in vascular
diameter with the cardiac cycle. Thus, vascular parameters that
are robust to pulse driven variability may be useful for screening
programs. A challenge in this regard will be whether AD related
changes are tractable from age, atherosclerosis and vascular
disease related abnormalities. Moreover, whether retinal vascular
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FIGURE 4 | Summary of eye and brain biomarkers of AD. APP, amyloid precursor protein; PS1/PS2, presenilin-1 −2, ERG, electroretinography; CSF,
cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography; FDG-PET, fluorodeoxyglucose-PET; RNFL, retinal nerve fiber layer; VEP,
visual evoked potential.
changes can differentiate mild cognitive impairment from AD is
as yet unclear.
Choroidal Thickness
Enhanced depth imaging (EDI) capabilities in modern OCT
devices employing longer wavelengths in the range of 1060 nm
(Wong et al., 2011) which allows for greater penetration into the
deeper layers of the eye, allowing visualization of the choroid.
The choroid which sits between the retina and the outer coat
of the eye, accounts for the majority of the blood supply to the
retina. A number of studies have assessed choroidal thickness
changes in AD. Gharbiya et al. (2014) demonstrated that the
choroid immediately below and within 1mm around the fovea
was ∼30% thinner in AD participants (n = 21) compared with
healthy controls (n= 21). A 20% thinning of the choroid has also
been reported by Bulut et al. (2016). Interestingly, Gharbiya et al.
(2014) did not find reduced RNFL thickness. While this suggests
that choroidal thinning preceded RNFL changes in AD, this
should be interpreted with some care given the small sample size,
potential noise generated from single-line manual segmentation
of the choroid (Cho et al., 2014) and lack of control for signal
strength (Ong et al., 2014).
Whilst better segmentation algorithms are already available to
overcome the current limitations, the biggest challenge is that
choroidal thinning undergoes significant diurnal fluctuations
(Kinoshita et al., 2016) and its thinning is seen in many
other conditions, including aging (Barteselli et al., 2012),
myopia (Ho et al., 2013), uveitis (Baltmr et al., 2014), chronic
obstructive pulmonary disease (Ozcimen et al., 2016). It also
has limited application in the detection of age-related macular
degeneration (Pilotto et al., 2015; Yiu et al., 2015) and
glaucoma (Li et al., 2015; Toprak et al., 2016). Again, spatial
mapping of choroidal thicknesses in relation to RNFL thinning
may reveal specific areas of the eye that are more specific
for Alzheimer’s disease. This need for specificity underlies
studies that have attempted to image hallmark AD deposits in
the retina.
Intraretinal Amyloid and Tau Deposition
In humans, Löﬄer et al. (1995) provided a histological
demonstration that APP and Aβ accumulated (extracellularly, in
sub-retinal deposits) in normal aged retinas. It was not known if
any of these patients had AD prior to death. It has been known
formore than a decade that Aβ is found in drusen deposits in eyes
with age-related macular degeneration but not in normal retinas
(Johnson et al., 2002; Dentchev et al., 2003; Anderson et al., 2004).
More recent findings suggest that Aβ deposits might also occur
inside retinal neurons.
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Studies in animal models confirmed that APP is expressed by
retinal ganglion cells, in the inner nuclear layer of the retina (cell
bodies of bipolar, amacrine and horizontal cells) and in the retinal
pigment epithelium. These cell classes also express β-secretase
and are capable of producing Aβ (for review, see Ratnayaka et al.,
2015). In genetically modified mice that have abnormalities in
APP processing, Aβ accumulates sporadically within the RGC
(Dutescu et al., 2009; Du et al., 2015), in the plexiform layers
(Perez et al., 2009), in the nuclear layers (Shimazawa et al., 2008),
in blood vessel walls (Liu et al., 2009), Bruch’s membrane, outer
segments of photoreceptors (Hoh et al., 2010) and within the
retinal pigment epithelium (Park et al., 2014). In humans, Hoh
et al. (2010) also reported that Aβ accumulated in photoreceptor
outer segments in post-mortem retina of AD patients. Given that
PET imaging detected amyloid deposition in the brain well before
the onset of clinical symptoms in AD (Pike et al., 2007; Rowe
et al., 2007), retinal imaging of in vivo Aβ accumulation is an
exciting prospect.
Tagging AD Deposits
Koronyo-Hamaoui et al. (2011) were first to demonstrate
successful non-invasive in vivo visualization of curcumin
bound flurorescent Aβ in the retinas of bitransgenic mice
(APPswe/PS11E9), with mutations to genes that regulate APP and
PS-1. They verified these findings using immunohistochemistry
co-labeling via anti-Aβ specific antibodies and Thioflavin-S. By
vaccinating with an altered myelin-derived peptide (MOG45D),
which has been shown to reduce Aβ plaques in the brain
(Koronyo-Hamaoui et al., 2009), the authors showed that retinal
deposits behave in a similar way, with fewer and smaller
Aβ plaques. Specific curcumin binding of Aβ has also been
demonstrated in donor brains and retinas from AD patients. No
such staining was seen in healthy controls of the same age. The
Commonwealth Scientific and Industrial Research Organization
(CSIRO, Australia) have shown promising preliminary data in
humans employing curcumin contrast in patients confirmed to
have deposits in the brain using PiB-PET imaging (Frost et al.,
2014).
Though promising, other studies have not found the same
outcome. Schön et al. (2012) in a small sample of 6 post-
mortem retinas from confirmed AD patients failed to find Aβ
plaques. They also report that they were unable to detect Aβ
plaques in vivo using amyloid-binding fluorophores (BSc4090)
in APPswe/PS11E9 mice. Schön et al. (2012) suggest that
hyperphosphorylated tau could potentially be a better marker
for the disease, having demonstrated its presence in the retina
of the P301S human tau mouse line using in vivo scanning laser
ophthalmoscopy imaging of (trans,trans)-1-fluoro-2,5-bis(3-
hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB)-bound tau
aggregates. These tau aggregates were also present in 5 out of
6 of the AD human retinas studied. However, Ho et al. (2014)
failed to find either phospho-tau deposits or Aβ in the retina of
11 confirmed AD donors using standard histological techniques,
including Aβ antibodies, thioflavin and congo red, that are
well established for brain tissue. The authors conclude that AD
hallmarks do not deposit in the eye in a manner analogous to
the brain, though they concede that the use of different assays;
limited retinal cross sections instead of wholemount; and paraffin
embedded sections instead of frozen tissues; might limit the
sensitivity in the detection of these proteins.
Visualizing AD Deposits without Tagging
Newer imaging modalities that target specific reflectance
characteristics of biological material hold the promise of being
non-invasive, contrast agent free and potentially specific. One
such method is hyperspectral imaging, whereby tissue reflectance
to a wide range of incident wavelengths are quantified (More
and Vince, 2015). Using this technique, More and Vince (2015)
were able to determine that Aβ has a unique hyperspectral
signature, capable of distinguishing these deposits in ex vivo
preparations of brain and retina from a mouse model of AD.
More recently, the authors applied this technology to a live
mouse retina, demonstrating that the hyperspectral signatures
are preserved even when imaged through the ocular media. This
discovery provides the first evidence for the non-invasive in vivo
detection of AD using hyperspectral imaging without the need
for an extraneous agent (More et al., 2016).
Another emerging imaging technique is the use of cross-
polarizers to distinguish ex vivo human donor retinas with AD
from controls (Campbell et al., 2015; Hamel et al., 2016). This
method capitalizes on the fibrillary arrangement of Aβ resulting
in specific changes to birefringence that are quantifiable using
Mueller matrix polarimetry. Along these lines, the advent of
PS-OCT may also prove to be useful.
Direct visualization of AD hallmarks with or without a
contrast enhancing agent in the retina may be considered the
most promising biomarker due to its specificity for the disease.
However, ongoing work is needed to verify that Aβ plaques or
accumulations, are indeed present in human retinal tissues; and
that such deposits indicate or are predictive of brain deposits.
Electrophysiological Signature
Functional change in the electrical response of specific brain
regions may be early markers in AD. This might arise as neuronal
changes signaling damage which may precede the conversion to
clinical disease (Alberdi et al., 2016). Not surprisingly, researchers
have measured visually evoked potentials, using electrodes on
scalp overlying the occipital region on either side of inion, as
a way to differentiate AD and healthy control volunteers. A
checkerboard stimulus that is reversing in contrast produces P1
and N1 components that are substantially reduced in patients
with advanced AD (Parisi et al., 2001; Stothart et al., 2015).
This is associated with losses in the retinal ganglion cell derived
pattern electroretinogram, which is measured using electrodes
on the eye in response to the same stimulus (Parisi et al.,
2001; Stothart et al., 2015). Furthermore, studies using multifocal
electroretinogram, which uses finer checks to allow spatial
localization of responses to small patches of retina, have shown
changes in the macular region in early AD patients (Moschos
et al., 2012). Electroretinogram deficits have also been found
in murine models of Aβ deposition (Perez et al., 2009; Krantic
and Torriglia, 2014). More recently, Parthasarathy et al. (2015)
and Gupta et al. (2016) showed an association between Aβ
burden in the retina and inner retinal function; suggesting altered
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TABLE 2 | Ocular changes associated with Alzheimer’s disease.
Structure Biomarker Highlights
Pupils Pupil flash responsea High speed video pupillography
a. Reduced mean constriction velocity
• sensitivity 0.74, specificity 0.71, AUC 0.76
b. Reduced maximum constriction, AUC 1.0
c. Constriction amplitude decreased in AD with repeated flashing
Lens Aβ accumulation in supranuclear layerb Topical Aftobetin hydrochloride ointment with fluorescent ligand eye scanning system
shows greater fluorescence in AD vs. HC.
• sensitivity 0.85, specificity 0.95, AUC 0.915
Retina Aβ hallmark detectionc a. Curcumin (injected and/or orally administered) binding to amyloid in mouse retina,
fundus camera.
b. Hyperspectral analysis distinguishes normal from AD mice.
c. Amyloid fibrillary signature detected using Mueller matrix polarimetry.
OCTd a. Retinal nerve fiber layer thinning
• Superior RNFL, AUC 0.60
• Macula Ganglion Cell complex, AUC 0.66
b. Choroidal layer thinning using EDI-OCT
Vascular changese a. Retinal venous blood flow reduction
b. Retinal vessel width reduction
c. Retinal vessel increased tortuosity
d. Retinal vessel increased branching complexity
Electroretinogram Visual Evoked Potentialf e. Pattern Electroretinogram: Slower N35, P50 implicit time and reduced P50 and N95
amplitudes
f. Multifocal Electroretinogram: reduced P1 amplitudes
g. Pattern Visual Evoked Potential: Slower P100 implicit time
Optic Nerve Pallorg Optic disk color analyzed using Laguna Optic Nerve Hemoglobin software shows
reduced optic nerve hemoglobin in AD.
This table shows a summary of key studies documenting ocular manifestations in Alzheimer’s disease.
aPrettyman et al. (1997), Fotiou et al. (2000), Fotiou et al. (2007), Frost et al. (2013a), Bittner et al. (2014).
bKerbage et al. (2013, 2015).
cKoronyo-Hamaoui et al. (2011), Campbell et al. (2015), More and Vince (2015).
dParisi et al. (2001), Iseri et al. (2006), Berisha et al. (2007), Paquet et al. (2007), Lu et al. (2010), Kesler et al. (2011), Kirbas et al. (2013), Moreno-Ramos et al. (2013), Ascaso et al.
(2014), Larrosa et al. (2014), Cheung et al. (2015).
eBerisha et al. (2007), de Jong et al. (2011), Cheung et al. (2014), Frost et al. (2013b), Feke et al. (2015), Williams et al. (2015).
fParisi et al. (2001) Krasodomska et al. (2010), Sartucci et al. (2010), Moschos et al. (2012), Stothart et al. (2015)
gTsai et al. (1991), Bambo et al. (2015).
neurotransmission between photoreceptors and inner retinal
cells.Whether such changes are specific to AD remains to be seen.
NON-RETINAL BIOMARKERS
Pupillary Reactions
Pupil size and the pupillary response to light is determined by
the balance of forces exerted by the iris sphincter and dilator
muscles. The former is influenced by cholinergic receptors found
in the parasympathetic system originating from the Edinger-
Westphal nucleus; whilst the latter is innervated by noradrenaline
receptor based postganglionic sympathetic system arising from
the superior cervical ganglion. It is well established in AD
that selective nicotinic acetylcholine receptor loss accounts for
symptoms closely associated with the severity of the disease
(Buckingham et al., 2009). Indeed, four out of the five US
Food and Drug Administration approved treatments for AD are
cholinesterase inhibitors, which promote neurotransmission and
masks some of the symptoms of AD.
Scinto et al. (1994) proposed the use of a clinical “pupil
dilation test” to expose AD cholinergic dysfunction. Central
cholinergic depletion results in upregulation of peripheral
receptors and thus hypersensitivity to cholinergic agonists, or
a reduced sensitivity to cholinergic antagonists. Using a dilute
agonist such as pilocarpine 0.0625% (Idiaquez et al., 1994)
or muscarinic antagonist such as tropicamide 0.01% induced
an abnormally large pupillary constriction or dilation in AD
patients, respectively. An alternative explanation was offered by
Hou et al. (2006) who showed evidence that the locus coeruleus of
the brain was responsible for adrenergic iris dilator input; which
when damaged in AD resulted in less sympathetic monotone
resistance to low dose tropicamide in AD. Recent studies have
been unable to replicate these findings. In a review of more than
20 available studies on the subject, Frost et al. (2010) concluded
that the reliability of a “pupil dilation test” for AD remained
questionable.
Given that cholinergic neurotransmission is altered in AD, this
might result in a change in the pupil’s response to light. Indeed, a
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decrease in pupil diameter response to abrupt changes in room
illumination (Prettyman et al., 1997) or a single flash of light
(known as the pupil flash response, PFR) has shown promise as
a biomarker for AD (Fotiou et al., 2000). The latter study went
on to show that the PFR parameter that best distinguished AD
patients from healthy controls was the maximum constriction
acceleration (Fotiou et al., 2007). Others have also linked PFR
changes to amyloid plaque burden in the brain (Frost et al.,
2013) and were also able to distinguish asymptomatic carriers
of an amyloid beta gene mutation (APPGlu693Gln) from non-
carriers (Frost et al., 2013). Whilst standard flash pupillometry
was able to distinguish AD from healthy controls, only subtle
timing differences were reported between groups.
Modifications are therefore being developed to enhance the
sensitivity of this technique such as the use of chromatic light to
target specific susceptible neurons in the retina, in particular the
retinal ganglion cells (Rukmini et al., 2015). Another possibility
is the use of a slower flash with an upwards “ramp” of increasing
intensity may draw out more subtle differences in maximum
constriction acceleration (Lei et al., 2014).
To this end, Bittner et al. (2014) suggest that repetitive
flashes fatigue the system resulting in more pronounced PFR
amplitude attenuation in AD and MCI patients compared with
healthy controls, and correlated better with cognitive test scores
(MMSE). They hypothesized that repeated light stimulation
in AD patients challenges the interaction between a deficient
sympathetic tone and parasympathetic overtone, resulting in
smaller pupils and progressive loss of amplitude. Taken together,
these studies show that pupil flash responses using high-speed
video-pupillography might be a promising biomarker as it is
directly assesses cholinergic integrity in the nervous system. It
remains to be seen whether taking AD medications such as
cholinesterase inhibitors blunt this effect. Certainly, more studies
are required to establish the reliability and repeatability of this
emerging technology.
Imaging the Crystalline Lens
The role of the crystalline lens is to focus incident light from the
outside world onto the retina. Primarily composed of crystallin
proteins, the high protein concentration and clear optics presents
an opportunity for researchers to study protein aggregation in
the eye. Aβ has been shown to deposit in the crystalline lenses
of monkeys, rats, rabbits (Frederikse et al., 1996) and transgenic
mice (Frederikse and Ren, 2002). Goldstein et al. (2003) first
reported the discovery of an AD specific cataract in humans,
where they show Aβ deposits in the cytoplasm of the equatorial
supranuclear/deep cortical lens fiber cells. This “AD cataract”
does not impair vision and is difficult to detect in a routine eye
examination unless a full dilation is achieved (Moncaster et al.,
2010). Others were unable to detect Aβ in the lens using either
standard immunohistochemistry methods (Michael et al., 2013;
Ho et al., 2014) or confocal Raman spectroscopy (Michael et al.,
2014). In a clinical study, Bei et al. (2015) did not find specific
cataracts in a cohort of AD patients whose pathology have been
confirmed using both PiB-PET imaging and CSF analysis.
Kerbage et al. (2013) suggested using a florescent amyloid
binding ligand in order to maximize the chances of detecting
Aβ in the lens. By compounding the ligand substance (aftobetin
hydrochloride) into a sterile ophthalmic ointment suitable for
topical application; in combination with an in vivo pulsed laser
fluorescent spectroscopy in a group of 20 AD and 20 healthy
controls the authors were able to detect supranuclear amyloid
in the lens of most AD patients with a sensitivity of 85% and
specificity of 95% (Kerbage et al., 2015). The authors found a
correlation between fluorescence uptake values in the lens with
amyloid burden in the brain detected quantified using PET.
Despite the promise of Kerbage et al.’s (2013) recent study
as a whole, the literature indicates that the presence of Aβ
in the human lens remains to be confirmed. Nevertheless, it
appears that fluorescently labeling Aβ in the lens may provide
improved detection over conventional lenticular assessment.
Further studies are needed to establish this is the case in larger
cohorts of patients. Furthermore, ongoing studies are needed
to prove that the system is capable of not just detection but
potentially be able to stratify patients based on disease severity.
Table 2 summarizes the key studies which have shown promise
as utility of the eye as a biomarker for AD. Figure 5 schematically
highlights those sites in the eye which show evidence for changes
with AD as well as those currently being further investigated.
Eye Movements
It has been recognized that patients with AD suffer difficulty
with reading. This is in part due to suboptimal eye movements,
which has been suggested to be linked to memory function
(Fernández et al., 2014). It has been shown that AD sufferers
present with increased latency when initializing voluntary eye
movements, show decreased eye movement velocity, fail to fixate
on a target or move in the wrong direction entirely and also fail to
follow a moving target (Molitor et al., 2015). These fixation and
movement errors reflect damage to their neural generators within
the cortex and the brainstem. Although researchers have yet to
find a distinct AD signature, eye movements show potential as a
biomarker. Further studies are needed to establish a standardized
test battery specific to AD and to demonstrate the ability to
correlate oculomotor function with disease progression.
POTENTIAL FUTURE BIOMARKERS
Corneal Nerve Imaging
Corneal nerves are stratified into 3 layers and may be found
in between the basal epithelium and bowman’s layers (sub-
basal nerve plexus), in between the bowman’s layer and the
anterior stroma (sub-epithelial nerve plexus) and within the
stroma (stromal nerve plexus). Corneal nerve imaging has
clinical utility post-corneal surgery as well as in diseased state
such as keratoconus (a corneal ectasia), dry eyes and in diabetes
(Patel and McGhee, 2009). Nerve growth factor is essential for
the development and maintenance of neurons in the peripheral
nervous system and for the integrity of cholinergic neurons
in the central nervous system and in the cornea. As impaired
nerve growth factor retrograde transport has been linked to
cholinergic neurodegeneration in AD (Aloe et al., 2012) corneal
nerve integrity might prove useful as a biomarker for the
disease. Preliminary steps are being taken to be able to image
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FIGURE 5 | Anatomical representation of Ocular biomarkers. Figure illustrates ocular biomarkers which have shown changes in AD patients as well as potential
future ocular biomarkers as marked by location in the eye. Images are broadly representative of the techniques employed in studies. Red arrows denote where
measurements are typically taken.
axonal transport in vivo (Abbott et al., 2013; Takihara et al.,
2015). As corneal nerves can be imaged directly, a functional
measure of axonal transport may prove to be more specific
for AD.
Ocular Fluid Biomarkers
Proteomics have been increasingly used since the 1990’s for
large scale analysis of proteins in health and diseases, such as
AD (Butterfield, 2004). Proteomic analyses of aqueous humor
samples have revealed the presence of AD related peptides. Tear
fluid, being easy to access has also shown promise in the detection
of neurodegenerative diseases such as glaucoma (Tezel, 2013) and
was recently shown to be clinically viable (Kalló et al., 2016).
Micro RNA (miRNA) has gained significant attention as
a class of non-coding regulatory RNA molecules capable of
modifying gene expression at the post-transcriptional level by
binding to the un-translated region of their target mRNAs.
Several candidate miRNA namely hsa-miR-106, −153, −101,
−29, −107 have already been shown to be implicated in
regulating amyloid production (Kumar et al., 2013). That
miRNA molecules have been isolated in tears warrants
further studies as to their feasibility as a fluid biomarker
for AD.
SUMMARY
Only five treatments are currently approved by the United States
Food and Drug Administration for AD, namely, rivastigmine,
galantamine, tacrine, donepril and memantine. These are all
cholinesterase inhibitors with the exception of memantine, which
is an NMDA (N-methyl-D-aspartate) receptor antagonist. These
medications delay the worsening of the symptoms in AD for
some 6 to 12 months and work in about half of patients (Casey
et al., 2010). As yet there is no approved treatment targeting
the pathophysiological mechanisms underlying AD. Current
candidate AD drugs include those that target either Aβ, APP,
or tau metabolism by preventing oligomer eﬄux, modulating
enzyme secretases, prevent aggregation, facilitate clearance and
vaccination induced immunological clearance (Kumar et al.,
2015). To test such drugs reliable and sensitive laboratory and
clinical readouts are needed.
The discovery of AD biomarkers such as PET imaging and
CSF molecules have considerably advanced our understanding of
the disease. These biomarkers are crucial for disease monitoring
and the recruitment of preclinical AD patients for clinical
trials. Despite the success of these established biomarkers,
their widespread implementation remains a challenge. Ocular
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biomarkers for AD are still in their infancy and are not
without their limitations. Many of the potential biomarkers
discussed share substantial overlap with ocular and systemic
diseases. Currently, the ocular biomarkers holding the most
promise are those specific for AD pathophysiological such as
the detection of Aβ-related retina changes. Additionally or
alternatively, a battery of clinical functional and structural ocular
assessments may improve specificity for AD. Eye care practices
are well positioned to provide these technologies to the public.
Already, sensitive imaging modalities such as fundus cameras
and OCT are commonplace in eye clinics. Emerging technologies
such as OCT angiography (using OCT to resolve the smallest
blood vessels), EDI-OCT and PS-OCT will contribute to the
increase in sensitivity and diagnostic capacity for the disease.
With advances in this area, primary eye care practitioners
may play a larger role in the provision of care for patients
with Alzheimer’s disease. A range of neurological diseases
including AD, Parkinson’s disease, frontotemporal dementia,
vascular dementia, Neimann-Pick disease may stand to benefit
from ocular biomarker technology, as a means to improve
understanding, monitoring and to help facilitate of discovery of
therapies.
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